L-carnitine and contribution to normal lipid metabolism

evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel), Dominique Turck, Jean Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Anders Sjödin, Martin Stern, Daniel Tomé, Henk Van Loveren, Marco Vinceti & 4 others Peter Willatts, Ambroise Martin, Sean (J. J.). Strain, Alfonso Siani

Research output: Contribution to journalArticle

29 Downloads (Pure)

Abstract

Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is sufficiently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L-carnitine and contribution to normal lipid metabolism in the target population.

Original languageEnglish
Article numbere05137
Pages (from-to)1-9
Number of pages9
JournalEFSA Journal
Volume16
Issue number1
Early online date16 Jan 2018
DOIs
Publication statusPublished - Jan 2018

Fingerprint

health claims
Carnitine
carnitine
Lipid Metabolism
lipid metabolism
Health Services Needs and Demand
Health
Food
Dietetics
dietetics
hypersensitivity
Germany
Hypersensitivity
nutrition
nutrients
Population

Keywords

  • health claim
  • L-carnitine
  • lipid metabolism

Cite this

EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel), Turck, D., Bresson, J. L., Burlingame, B., Dean, T., Fairweather-Tait, S., ... Siani, A. (2018). L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal, 16(1), 1-9. [e05137]. https://doi.org/10.2903/j.efsa.2018.5137
EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel) ; Turck, Dominique ; Bresson, Jean Louis ; Burlingame, Barbara ; Dean, Tara ; Fairweather-Tait, Susan ; Heinonen, Marina ; Hirsch-Ernst, Karen Ildico ; Mangelsdorf, Inge ; McArdle, Harry J. ; Naska, Androniki ; Neuhäuser-Berthold, Monika ; Nowicka, Grażyna ; Pentieva, Kristina ; Sanz, Yolanda ; Sjödin, Anders ; Stern, Martin ; Tomé, Daniel ; Van Loveren, Henk ; Vinceti, Marco ; Willatts, Peter ; Martin, Ambroise ; Strain, Sean (J. J.). ; Siani, Alfonso. / L-carnitine and contribution to normal lipid metabolism : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. In: EFSA Journal. 2018 ; Vol. 16, No. 1. pp. 1-9.
@article{987bb5b4d021481aae94696ad2712b7d,
title = "L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006",
abstract = "Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is sufficiently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L-carnitine and contribution to normal lipid metabolism in the target population.",
keywords = "health claim, L-carnitine, lipid metabolism",
author = "{EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel)} and Dominique Turck and Bresson, {Jean Louis} and Barbara Burlingame and Tara Dean and Susan Fairweather-Tait and Marina Heinonen and Hirsch-Ernst, {Karen Ildico} and Inge Mangelsdorf and McArdle, {Harry J.} and Androniki Naska and Monika Neuh{\"a}user-Berthold and Grażyna Nowicka and Kristina Pentieva and Yolanda Sanz and Anders Sj{\"o}din and Martin Stern and Daniel Tom{\'e} and {Van Loveren}, Henk and Marco Vinceti and Peter Willatts and Ambroise Martin and Strain, {Sean (J. J.).} and Alfonso Siani",
year = "2018",
month = "1",
doi = "10.2903/j.efsa.2018.5137",
language = "English",
volume = "16",
pages = "1--9",
journal = "EFSA Journal",
issn = "1831-4732",
publisher = "Wiley",
number = "1",

}

EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel), Turck, D, Bresson, JL, Burlingame, B, Dean, T, Fairweather-Tait, S, Heinonen, M, Hirsch-Ernst, KI, Mangelsdorf, I, McArdle, HJ, Naska, A, Neuhäuser-Berthold, M, Nowicka, G, Pentieva, K, Sanz, Y, Sjödin, A, Stern, M, Tomé, D, Van Loveren, H, Vinceti, M, Willatts, P, Martin, A, Strain, SJJ & Siani, A 2018, 'L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006', EFSA Journal, vol. 16, no. 1, e05137, pp. 1-9. https://doi.org/10.2903/j.efsa.2018.5137

L-carnitine and contribution to normal lipid metabolism : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. / EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel); Turck, Dominique; Bresson, Jean Louis; Burlingame, Barbara; Dean, Tara; Fairweather-Tait, Susan; Heinonen, Marina; Hirsch-Ernst, Karen Ildico; Mangelsdorf, Inge; McArdle, Harry J.; Naska, Androniki; Neuhäuser-Berthold, Monika; Nowicka, Grażyna; Pentieva, Kristina; Sanz, Yolanda; Sjödin, Anders; Stern, Martin; Tomé, Daniel; Van Loveren, Henk; Vinceti, Marco; Willatts, Peter; Martin, Ambroise; Strain, Sean (J. J.).; Siani, Alfonso.

In: EFSA Journal, Vol. 16, No. 1, e05137, 01.2018, p. 1-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - L-carnitine and contribution to normal lipid metabolism

T2 - evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel)

AU - Turck, Dominique

AU - Bresson, Jean Louis

AU - Burlingame, Barbara

AU - Dean, Tara

AU - Fairweather-Tait, Susan

AU - Heinonen, Marina

AU - Hirsch-Ernst, Karen Ildico

AU - Mangelsdorf, Inge

AU - McArdle, Harry J.

AU - Naska, Androniki

AU - Neuhäuser-Berthold, Monika

AU - Nowicka, Grażyna

AU - Pentieva, Kristina

AU - Sanz, Yolanda

AU - Sjödin, Anders

AU - Stern, Martin

AU - Tomé, Daniel

AU - Van Loveren, Henk

AU - Vinceti, Marco

AU - Willatts, Peter

AU - Martin, Ambroise

AU - Strain, Sean (J. J.).

AU - Siani, Alfonso

PY - 2018/1

Y1 - 2018/1

N2 - Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is sufficiently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L-carnitine and contribution to normal lipid metabolism in the target population.

AB - Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is sufficiently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L-carnitine and contribution to normal lipid metabolism in the target population.

KW - health claim

KW - L-carnitine

KW - lipid metabolism

UR - http://www.scopus.com/inward/record.url?scp=85062077789&partnerID=8YFLogxK

U2 - 10.2903/j.efsa.2018.5137

DO - 10.2903/j.efsa.2018.5137

M3 - Article

VL - 16

SP - 1

EP - 9

JO - EFSA Journal

JF - EFSA Journal

SN - 1831-4732

IS - 1

M1 - e05137

ER -

EFSA Panel on Dietetic Products, Nutrition and Allergies (EFSA NDA Panel), Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S et al. L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA Journal. 2018 Jan;16(1):1-9. e05137. https://doi.org/10.2903/j.efsa.2018.5137